Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427176 | 1.00 | NMBR (0.51) | NMBRSIRT2CTSSCTSKCTSL | |
| SCHEMBL30665993 | 0.90 | NMBR (0.44) | NMBRSIRT2CTSSCTSKCTSL | |
| SCHEMBL5353860 | 0.90 | SIRT2 (0.50) | NMBRSIRT2CTSSCTSKCTSL | |
| SCHEMBL30277394 | 0.88 | NMBR (0.44) | NMBRSIRT2CTSS | |
| SCHEMBL9959535 | 0.88 | SIRT2 (0.53) | NMBRSIRT2 | |
| SCHEMBL29401183 | 0.88 | SIRT2 (0.53) | NMBRSIRT2 | |
| SCHEMBL5349888 | 0.88 | SIRT2 (0.53) | NMBRSIRT2 | |
| SCHEMBL30250367 | 0.88 | NMBR (0.42) | NMBRSIRT2CTSSCTSKCTSL | |
| SCHEMBL30120772 | 0.88 | SIRT2 (0.49) | NMBRSIRT2CTSSCTSKCTSL | |
| SCHEMBL18367552 | 0.88 | SIRT2 (0.49) | NMBRSIRT2CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | VECTIVBIO AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2025-06-12 | — | — | US | disclosed |
| US-20250049893-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2025-02-13 | — | — | US | disclosed |
| US-20240325500-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2024-10-03 | — | — | US | disclosed |
| US-20240252595-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2024-08-01 | — | — | US | disclosed |
| US-11766470-B2 | Manufacture, formulation and dosing of apraglutide | VECTIVBIO AG (CH) | 2023-09-26 | — | — | US | disclosed |
| US-20230241179-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2023-08-03 | — | — | US | disclosed |
| US-20230173033-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4161553-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VectivBio AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241179-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-11766470-B2 | Manufacture, formulation and dosing of apraglutide | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-20240252595-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-20230173033-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-20250049893-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
| US-20240325500-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | NMBR 1577/4885SIRT2 202/4885CTSS 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.